{"id":6166,"date":"2025-08-05T12:12:16","date_gmt":"2025-08-05T10:12:16","guid":{"rendered":"https:\/\/www.ehc.eu\/non-classifiee\/ehc-publie-la-deuxieme-edition-de-novel-treatment-review-en-2025\/"},"modified":"2026-04-02T16:31:51","modified_gmt":"2026-04-02T14:31:51","slug":"ehc-publie-la-deuxieme-edition-de-novel-treatment-review-en-2025","status":"publish","type":"post","link":"https:\/\/www.ehc.eu\/fr\/nouvelles\/ehc-publie-la-deuxieme-edition-de-novel-treatment-review-en-2025\/","title":{"rendered":"EHC publie la deuxi\u00e8me \u00e9dition de Novel Treatment Review en 2025"},"content":{"rendered":"<!-- hero -->\t<section   class=\"subpage-hero bg-white\">\n\t\t<div class=\"container\">\n\t\t\t<div class=\"relative z-10\">\n\t\t\t\t<div class=\"pt-16 lg:pt-24 pb-24 lg:pb-32\">\n\t\t\t\t\t<div class=\"row justify-between gap-10 lg:gap-0 mt-10 text-center lg:text-left\">\n\t\t\t\t\t\t<div class=\"w-full lg:w-6\/12 lg:self-center\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"title h2\" data-scroll data-fade-up>\n\t\t\t\t\t\t\t\t\t<p class=\"text-[115%]\">EHC publie la deuxi\u00e8me \u00e9dition de Novel Treatment Review en 2025<\/p>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<figure class=\"absolute size-[41.8rem] lg:size-[82.8rem] bottom-[-10%] right-[-10rem] lg:right-[-5%] image-contain opacity-100 skip-lazy\" data-parallax>\n\t\t\t\t\t<img decoding=\"async\" loading=\"eager\" src=\"https:\/\/etngbd86n6b.exactdn.com\/wp-content\/themes\/cbd\/img\/content-logo-colorfull-2.svg\" alt=\"content-logo-colorfull\">\n\t\t\t\t<\/figure>\n\t\t\t\t\t\t<\/section>\n<!-- overview -->\t<section   class=\"s-overlay-img s-padding bg-red\">\n\t\t<div class=\"container\">\n\t\t\t<div class=\"row w-full lg:flex-row justify-between text-center lg:text-left gap-14 lg:gap-0 relative z-10\">\n\t\t\t\t\t\t\t\t<div class=\"w-full lg:py-10\">\n\t\t\t\t\t<div class=\"bg-white min-h-full py-12 px-10 lg:py-24 lg:pl-24 xl:pl-44 relative radius-20 z-10\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"content mt-8\" data-scroll data-fade-up>\n\t\t\t\t\t\t\t\t<p>L\u2019EHC a publi\u00e9 le deuxi\u00e8me num\u00e9ro 2025 de <a href=\"https:\/\/academy.ehc.eu\/novel-treatment-product-reviews\/\" target=\"_blank\" rel=\"noopener\"><strong>sa Novel Treatment Review (NTR),<\/strong><\/a> une revue p\u00e9riodique des nouveaux traitements pour l\u2019h\u00e9mophilie, la maladie de von Willebrand (VWD) et d\u2019autres troubles h\u00e9morragiques rares.<\/p>\n<p>L\u2019objectif du NTR est de fournir des informations \u00e0 jour \u00e0 notre communaut\u00e9 \u00e9largie, en particulier aux organisations nationales membres (NMO) de l\u2019EHC, ainsi qu\u2019un aper\u00e7u g\u00e9n\u00e9ral du paysage en rapide \u00e9volution du d\u00e9veloppement de produits de coagulation dans les troubles h\u00e9morragiques rares.<\/p>\n<p>Les principaux moments forts de cette derni\u00e8re \u00e9dition incluent :<\/p>\n<ul>\n<li>La Medicines and Healthcare Products Regulatory Agency (MHRA) du Royaume-Uni a approuv\u00e9 le marstacimab de Pfizer, commercialis\u00e9 sous le nom Hympavzi, pour la pr\u00e9vention et la r\u00e9duction des saignements chez les patients \u00e2g\u00e9s de 12 ans et plus pr\u00e9sentant une h\u00e9mophilie s\u00e9v\u00e8re A ou B qui n\u2019ont pas d\u00e9velopp\u00e9 d\u2019inhibiteurs du facteur VIII ou IX.<\/li>\n<li>La Food and Drug Administration (FDA) des \u00c9tats-Unis a approuv\u00e9 le fitusiran, commercialis\u00e9 sous le nom de Qfitlia, comme traitement prophylactique de routine pour pr\u00e9venir ou r\u00e9duire les \u00e9pisodes de saignement chez les personnes \u00e2g\u00e9es de 12 ans et plus pr\u00e9sentant une h\u00e9mophilie A ou B, avec ou sans inhibiteurs ou anticorps pouvant r\u00e9duire l\u2019efficacit\u00e9 du traitement.<\/li>\n<li>Metagenomi m\u00e8ne des \u00e9tudes pr\u00e9cliniques pour faire progresser le MGX-001, sa th\u00e9rapie exp\u00e9rimentale d\u2019\u00e9dition g\u00e9n\u00e9tique pour l\u2019h\u00e9mophilie A, dans le but d\u2019entrer dans les essais cliniques en 2026.<\/li>\n<li>Pfizer met fin au d\u00e9veloppement et \u00e0 la commercialisation mondiale de Beqvez, sa th\u00e9rapie g\u00e9nique pour l\u2019h\u00e9mophilie B. L\u2019entreprise se concentrera plut\u00f4t sur le d\u00e9veloppement de Hympavzi, un inhibiteur des voies anti-facteurs tissulaires pour l\u2019h\u00e9mophilie A et B.<\/li>\n<\/ul>\n<p>L\u2019EHC souhaite exprimer sa gratitude au <a href=\"https:\/\/www.ehc.eu\/governance\/novel-treatment-review-ntr-committee\/\" target=\"_blank\" rel=\"noopener\"><strong>groupe de travail EHC NTR<\/strong><\/a> pour leur contribution au d\u00e9veloppement de cette question.<\/p>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"bottom mt-12\" data-scroll data-fade-up>\n\t\t\t\t\t\t\t\t<a href=\"https:\/\/academy.ehc.eu\/wp-content\/uploads\/2025\/08\/EHC-NTR-August-2025.pdf\" target=\"_blank\" class=\"btn with-icon\">\n\t\t\t\t\t\t\t\t\t<span>Read the NTR 2025 Issue Two<\/span>\n\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t<\/section>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":4,"featured_media":4714,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[64],"tags":[146,214],"class_list":["post-6166","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-nouvelles","tag-ntr","tag-publications"],"acf":[],"jetpack_featured_media_url":"https:\/\/etngbd86n6b.exactdn.com\/wp-content\/uploads\/2025\/08\/NTR-Aug-2025-Blog-banner.jpg?strip=all&sharp=1","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/www.ehc.eu\/fr\/wp-json\/wp\/v2\/posts\/6166","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ehc.eu\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ehc.eu\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ehc.eu\/fr\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ehc.eu\/fr\/wp-json\/wp\/v2\/comments?post=6166"}],"version-history":[{"count":1,"href":"https:\/\/www.ehc.eu\/fr\/wp-json\/wp\/v2\/posts\/6166\/revisions"}],"predecessor-version":[{"id":6167,"href":"https:\/\/www.ehc.eu\/fr\/wp-json\/wp\/v2\/posts\/6166\/revisions\/6167"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.ehc.eu\/fr\/wp-json\/wp\/v2\/media\/4714"}],"wp:attachment":[{"href":"https:\/\/www.ehc.eu\/fr\/wp-json\/wp\/v2\/media?parent=6166"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ehc.eu\/fr\/wp-json\/wp\/v2\/categories?post=6166"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ehc.eu\/fr\/wp-json\/wp\/v2\/tags?post=6166"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}